Buy/Sell Signals for NortonLifeLock Inc. (NLOK) and Titan Pharmaceuticals Inc. (TTNP)

You should consider shares of NortonLifeLock Inc. (NASDAQ:NLOK) and Titan Pharmaceuticals Inc. (NASDAQ:TTNP) if you are looking for a great stocks to invest in. Starting with the NLOK shares, which traded at $27.50 at the close of the recent session, gaining 2.69%. On Wednesday, the company’s shares shed $0.72 from its value which represented in intraday trading. The stock is now 7.76% higher in year-to-date (YTD) trading. NLOK’s intraday high was $27.51 while its lowest price touched $26.79. The stock’s 52-week high price is $27.46, which means the current price is at 0.15%. In terms of trading activity, the daily trading volume rose to 13925217 against 200-day average trading volume of 7,489,545 shares.

What are analyst forecasts for NortonLifeLock Inc. (NASDAQ:NLOK)?

At a consensus rating of 3.33, NLOK is trending as a streaking Hold, as it has been the case a month ago when 14 analysts called it a Hold. Two months ago, 14 analysts recommended, on average, that NLOK stock is a Hold. The Technology company’s shares’ overall bullish trend saw it close lower on Wednesday compared to its opening price of $26.84 on the day.

Forecasts for NortonLifeLock Inc. (NASDAQ:NLOK) give the stock a fair value for the growth of -10.0% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $25.00, which means the price per share could fall by nearly -$2.5. The price range target is between a low of $21.00 and a high of $32.00. The stock would need to gain by about $14.06 to hit the estimated high or 0.64% from its 12-month low.

The consensus among 17 analysts is that it is a good time for one to Hold in the NortonLifeLock Inc. 3 analysts rate NLOK as a Buy, with 0 of 17 analysts rate it as a Sell. 0 have valued the stock as Overweight and 12 have recommended that investors Hold.

NortonLifeLock Inc. (NASDAQ:NLOK) Upgrades and Downgrades

In terms of rating changes, Barclays on January 06, 2020, Upgrade NortonLifeLock Inc. (NLOK) at Overweight. They believe the stock could reach $32 in the near term. Analysts at Credit Suisse have assigned a Neutral rating for the stock in their research note on November 27, 2019 with an estimated price target of $26.

Titan Pharmaceuticals Inc. (NASDAQ:TTNP) adds $0.0 on Wednesday

The TTNP stock has risen 35.50% year-to-date and is currently trading at $0.26, which is -89.27% below its 52-week high. The company shares lost -0.75% on the day and have risen nearly 85.21% off a low hit. At current levels, Titan Pharmaceuticals Inc. has a valuation of about $3.60M. As of 01/15/20, this stock has risen 20.09% during the week and closed at $0.26 in the previous session. However, recent Titan Pharmaceuticals Inc. stock performance shows that TTNP shares are 60.37% up over the last month, and -28.44% down for the last three months.

Earnings per share (EPS) estimates for the current quarter are -$0.31, with the trailing 12-month share earnings at -$1.53. The ratio is expected to be up by 63.00% for the current year 2019 and 77.50% for next year. But will the TTNP stock surprise in the current quarter results, where the -$0.18 actual EPS reported on 9/29/2019 surprised by 14.30% or was higher by $0.03 from the estimated -$0.21.

Sales Growth to climb 69.90% for the year

How well will Titan Pharmaceuticals Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $450k and $1.4M in current quarter sales. The consensus estimated for the current quarter is $920k from sales. Forecasts for this fiscal year are between $2.84M and $3.8M and the consensus estimate for sales is at $3.32M. TTNP has its next quarter sales estimates at between $820k and $820k, with the quarter-over-quarter growth estimates at -25.50% and the annual growth forecast for the year at 69.90%.

Who owns shares in Titan Pharmaceuticals Inc. (TTNP)?

Let’s briefly focus on the share ownership of the Titan Pharmaceuticals Inc. (NASDAQ:TTNP) stock, where we find that 7.23% of shares are held by institutions. Vanguard Group, Inc. (The) tops the list of institutional owners as it is holding 543006.0 shares or 0.98% of shares outstanding. Sabby Management, LLC and Geode Capital Management, LLC held 83218.0 and 82664.0 representing 0.15% and 0.15% respectively at the close of the last trading session. As of Sep 29, 2019, Virtu Financial LLC accounted for 34640.0 shares at over 9318.0. This represented 0.06% of shares outstanding. HRT Financial LLC held 19620.0 shares at over 5277.0 representing 0.04% of shares outstanding.